Tag Archives: authorized

Only Todd Howard is ‘Authorized’ to Speak About Unreleased Starfield Game Info – GameRant

  1. Only Todd Howard is ‘Authorized’ to Speak About Unreleased Starfield Game Info GameRant
  2. Starfield’s Todd Howard Is the Only One “Authorized” to Talk About Unreleased Details ComicBook.com
  3. Todd Howard is the only person “authorised to talk publicly about unreleased” Starfield details Eurogamer.net
  4. Starfield’s studio design director pleads for people to stop asking questions because only ‘Todd Howard himself is authorised to talk’ PC Gamer
  5. Starfield devs would love to answer your questions, but “no one other than Todd Howard” can talk about the game Gamesradar
  6. View Full Coverage on Google News

Read original article here

Pope Francis authorized wire-tapping of financier

The Vatican authorized secret wiretaps on an Italian financial broker based in London who has been charged with defrauding the Holy See of hundreds of millions of dollars, according to leaked documents.

Pope Francis granted investigators the power to bug phones, intercept emails and arrest anyone without approval from British judges, The Times of London reported.

The Vatican’s Office of the Promoter of Justice used those powers to target millionaire Raffaele Mincione, a fund manager accused of cheating the Vatican amidst a roughly $350 million real estate venture.

The scandal centers on a massive Vatican investment in a former Harrod’s warehouse in London, which was set to be converted into luxury apartments.

Mincione is one of 10 people, including a cardinal, embroiled in the controversy, which first came to light in 2014. He has denied wrongdoing.

Last month, prosecutors questioned Mincione about his management of a fund that owned the London property.

Raffaele Mincione, a fund manager, is accused of cheating the Vatican of millions.
David M. Benett

In April 2021, the pope amended Vatican law, permitting religious leaders like cardinals and bishops to stand trial before the Vatican’s civilian-led courts, the Telegraph reported.

Days later Pope Francis allegedly ordered “the adoption of technological tools suitable for intercepting fixed and mobile devices, as well as any other communication, including electronic ones,” according to the leaked documents. “These powers may be exercised against subjects whose communication activities are considered useful for carrying out the investigations.”

Weeks later, Mincione’s phones and computer were seized by Vatican authorities and Italian police at a hotel in Rome, while the financier was vacationing, according to the report. His Italian lawyer claims he was put under surveillance.

Mincione’s attorney’s have written to British officials urging them not to cooperate with the Vatican’s investigation.

Read original article here

First Covid-19 breath test authorized by FDA

The FDA said the InspectIR Covid-19 Breathalyzer, which is about the size of a piece of carry-on luggage, can be used in medical offices and mobile testing sites. It can give results in less than three minutes.

The system separates and identifies chemical mixtures to detect five compounds associated with SARS-CoV-2 infection.

A study of the InspectIR Breathalyzer found that it accurately identified more than 91% of positive samples and nearly 100% of negative samples. Similar sensitivity was found in another study that focused on the Omicron coronavirus variant. However, a positive result should be confirmed with a PCR test, the FDA said.

“It’s another tool, and the FDA announcement suggests it’s reasonably accurate and a relatively user-friendly tool,” Dr. Emily Volk, president of the College of American Pathologists, a board-certified anatomic and clinical pathologist, said Friday.

“It waits to be seen how widely this will be adopted,” Volk said. “That could rely on how expensive it is.”

In an email to CNN on Friday, InspectIR Systems said it is not releasing the price of the machine or when it will be available.

The agency’s authorization “is yet another example of the rapid innovation occurring with diagnostic tests for COVID-19,” Dr. Jeff Shuren, director of the FDA’s Center for Devices and Radiological Health, said in a statement. “The FDA continues to support the development of novel COVID-19 tests with the goal of advancing technologies that can help address the current pandemic and better position the U.S. for the next public health emergency.”

Read original article here

Frank Vogel rumors: Lakers coach was authorized to bench Russell Westbrook, won’t be fired on Friday

The Los Angeles Lakers trailed the Indiana Pacers by only a single point when Russell Westbrook re-entered Wednesday’s game with 8:15 remaining in the fourth quarter. With under four minutes to go, their deficit had ballooned up to seven. This was hardly a surprise. 

The Lakers have been outscored by 34 points in Westbrook’s 342 fourth-quarter minutes this season. In the 198 fourth-quarter minutes they’ve played without him, they’ve outscored their opponents by 50 points. With yet another opportunity squandered on Westbrook’s watch, Vogel had seen enough. He pulled Westbrook out of the game at the 3:52 mark and never reinserted him. After the game, he was brutally honest about his decision. 

“Playing the guys that I thought were going to win the game,” Vogel explained when asked about Westbrook’s benching. It is a move that Lakers fans have clamored for all season, but one that will surely have enormous repercussions in the locker room. Westbrook is not only a former MVP, but one that LeBron James lobbied the team to acquire personally. 

But according to ESPN’s Dave McMenamin, Vogel was given the green light to bench Westbrook by the front office, whose approach over the past week and a half has been to allow Vogel to handle Westbrook as he saw fit. McMenamin noted that Westbrook failed to defend Pacers guard Caris LeVert as the game-plan emphasized that he should, which likely played a part in Westbrook getting benched.

Vogel himself is in an extremely precarious position. Reports have suggested that Vogel is currently coaching for his job, and that he was almost fired after the Lakers were dealt a 37-point loss to the Denver Nuggets on Saturday. Vogel will not be fired for the time being and will travel to Orlando to coach against the Magic on Friday, according to Yahoo’s Chris Haynes.

Vogel used six players after removing Westbrook: James, Carmelo Anthony, Austin Reaves, Talen Horton-Tucker, Avery Bradley and Malik Monk. Four of those players, like Westbrook, are guards. Another significant guard, Kendrick Nunn, is slated for a major role when he returns from the injury that has held him out all season. It is therefore worth asking what exactly Westbrook’s role will be moving forward if Vogel is finally willing to allocate his minutes based on performance over reputation. Might Westbrook be forced to come off of the bench rather than start? The Lakers could try to trade Westbrook before the Feb. 10 deadline, but according to Bleacher Report’s Eric Pincus, the market for him is “nonexistent.”

For now, that means that all the Lakers can do is hold Westbrook accountable for his play. He is shooting 30.2 percent from the field in his last seven games. He’s been a defensive liability all season and the Lakers have played better with him on the bench by virtually every statistical marker. That is not the sort of player that deserves to close games, and if Wednesday was any indication, that’s a role Westbrook will have to earn back if it’s one he wants to have at all.

require.config({"baseUrl":"https://sportsfly.cbsistatic.com/fly-0141/bundles/sportsmediajs/js-build","config":{"version":{"fly/components/accordion":"1.0","fly/components/alert":"1.0","fly/components/base":"1.0","fly/components/carousel":"1.0","fly/components/dropdown":"1.0","fly/components/fixate":"1.0","fly/components/form-validate":"1.0","fly/components/image-gallery":"1.0","fly/components/iframe-messenger":"1.0","fly/components/load-more":"1.0","fly/components/load-more-article":"1.0","fly/components/load-more-scroll":"1.0","fly/components/loading":"1.0","fly/components/modal":"1.0","fly/components/modal-iframe":"1.0","fly/components/network-bar":"1.0","fly/components/poll":"1.0","fly/components/search-player":"1.0","fly/components/social-button":"1.0","fly/components/social-counts":"1.0","fly/components/social-links":"1.0","fly/components/tabs":"1.0","fly/components/video":"1.0","fly/libs/easy-xdm":"2.4.17.1","fly/libs/jquery.cookie":"1.2","fly/libs/jquery.throttle-debounce":"1.1","fly/libs/jquery.widget":"1.9.2","fly/libs/omniture.s-code":"1.0","fly/utils/jquery-mobile-init":"1.0","fly/libs/jquery.mobile":"1.3.2","fly/libs/backbone":"1.0.0","fly/libs/underscore":"1.5.1","fly/libs/jquery.easing":"1.3","fly/managers/ad":"2.0","fly/managers/components":"1.0","fly/managers/cookie":"1.0","fly/managers/debug":"1.0","fly/managers/geo":"1.0","fly/managers/gpt":"4.3","fly/managers/history":"2.0","fly/managers/madison":"1.0","fly/managers/social-authentication":"1.0","fly/utils/data-prefix":"1.0","fly/utils/data-selector":"1.0","fly/utils/function-natives":"1.0","fly/utils/guid":"1.0","fly/utils/log":"1.0","fly/utils/object-helper":"1.0","fly/utils/string-helper":"1.0","fly/utils/string-vars":"1.0","fly/utils/url-helper":"1.0","libs/jshashtable":"2.1","libs/select2":"3.5.1","libs/jsonp":"2.4.0","libs/jquery/mobile":"1.4.5","libs/modernizr.custom":"2.6.2","libs/velocity":"1.2.2","libs/dataTables":"1.10.6","libs/dataTables.fixedColumns":"3.0.4","libs/dataTables.fixedHeader":"2.1.2","libs/dateformat":"1.0.3","libs/waypoints/infinite":"3.1.1","libs/waypoints/inview":"3.1.1","libs/waypoints/jquery.waypoints":"3.1.1","libs/waypoints/sticky":"3.1.1","libs/jquery/dotdotdot":"1.6.1","libs/jquery/flexslider":"2.1","libs/jquery/lazyload":"1.9.3","libs/jquery/maskedinput":"1.3.1","libs/jquery/marquee":"1.3.1","libs/jquery/numberformatter":"1.2.3","libs/jquery/placeholder":"0.2.4","libs/jquery/scrollbar":"0.1.6","libs/jquery/tablesorter":"2.0.5","libs/jquery/touchswipe":"1.6.18","libs/jquery/ui/jquery.ui.core":"1.11.4","libs/jquery/ui/jquery.ui.draggable":"1.11.4","libs/jquery/ui/jquery.ui.mouse":"1.11.4","libs/jquery/ui/jquery.ui.position":"1.11.4","libs/jquery/ui/jquery.ui.slider":"1.11.4","libs/jquery/ui/jquery.ui.sortable":"1.11.4","libs/jquery/ui/jquery.ui.touch-punch":"0.2.3","libs/jquery/ui/jquery.ui.autocomplete":"1.11.4","libs/jquery/ui/jquery.ui.accordion":"1.11.4","libs/jquery/ui/jquery.ui.tabs":"1.11.4","libs/jquery/ui/jquery.ui.menu":"1.11.4","libs/jquery/ui/jquery.ui.dialog":"1.11.4","libs/jquery/ui/jquery.ui.resizable":"1.11.4","libs/jquery/ui/jquery.ui.button":"1.11.4","libs/jquery/ui/jquery.ui.tooltip":"1.11.4","libs/jquery/ui/jquery.ui.effects":"1.11.4","libs/jquery/ui/jquery.ui.datepicker":"1.11.4"}},"shim":{"liveconnection/managers/connection":{"deps":["liveconnection/libs/sockjs-0.3.4"]},"liveconnection/libs/sockjs-0.3.4":{"exports":"SockJS"},"libs/setValueFromArray":{"exports":"set"},"libs/getValueFromArray":{"exports":"get"},"fly/libs/jquery.mobile-1.3.2":["version!fly/utils/jquery-mobile-init"],"libs/backbone.marionette":{"deps":["jquery","version!fly/libs/underscore","version!fly/libs/backbone"],"exports":"Marionette"},"fly/libs/underscore-1.5.1":{"exports":"_"},"fly/libs/backbone-1.0.0":{"deps":["version!fly/libs/underscore","jquery"],"exports":"Backbone"},"libs/jquery/ui/jquery.ui.tabs-1.11.4":["jquery","version!libs/jquery/ui/jquery.ui.core","version!fly/libs/jquery.widget"],"libs/jquery/flexslider-2.1":["jquery"],"libs/dataTables.fixedColumns-3.0.4":["jquery","version!libs/dataTables"],"libs/dataTables.fixedHeader-2.1.2":["jquery","version!libs/dataTables"],"https://sports.cbsimg.net/js/CBSi/app/VideoPlayer/AdobePass-min.js":["https://sports.cbsimg.net/js/CBSi/util/Utils-min.js"]},"map":{"*":{"adobe-pass":"https://sports.cbsimg.net/js/CBSi/app/VideoPlayer/AdobePass-min.js","facebook":"https://connect.facebook.net/en_US/sdk.js","facebook-debug":"https://connect.facebook.net/en_US/all/debug.js","google":"https://apis.google.com/js/plusone.js","google-platform":"https://apis.google.com/js/client:platform.js","google-csa":"https://www.google.com/adsense/search/async-ads.js","google-javascript-api":"https://www.google.com/jsapi","google-client-api":"https://apis.google.com/js/api:client.js","gpt":"https://securepubads.g.doubleclick.net/tag/js/gpt.js","newsroom":"https://c2.taboola.com/nr/cbsinteractive-cbssports/newsroom.js","recaptcha":"https://www.google.com/recaptcha/api.js?onload=loadRecaptcha&render=explicit","recaptcha_ajax":"https://www.google.com/recaptcha/api/js/recaptcha_ajax.js","supreme-golf":"https://sgapps-staging.supremegolf.com/search/assets/js/bundle.js","taboola":"https://cdn.taboola.com/libtrc/cbsinteractive-cbssports/loader.js","twitter":"https://platform.twitter.com/widgets.js","video-avia":"https://vidtech.cbsinteractive.com/avia-js/1.9.0/player/avia.min.js","video-avia-cvui":"https://vidtech.cbsinteractive.com/avia-js/1.9.0/legacy/cvui/cvui.min.js","video-ima3":"https://imasdk.googleapis.com/js/sdkloader/ima3.js","video-ima3-dai":"https://imasdk.googleapis.com/js/sdkloader/ima3_dai.js","video-utils":"https://sports.cbsimg.net/js/CBSi/util/Utils-min.js","video-vast-tracking":"https://vidtech.cbsinteractive.com/sb55/vast-js/vtg-vast-client.js"}},"waitSeconds":300});



Read original article here

The US FDA has authorized 2 antiviral pills to treat Covid-19. Here’s what we know about them

The US Food and Drug Administration on Thursday authorized Merck’s antiviral pill, molnupiravir, to treat Covid-19.

This is the second Covid-19 antiviral pill authorized for ill people to take at home, before they get sick enough to be hospitalized. Merck has an agreement with the US government for the company to supply 3.1 million courses of molnupiravir upon this authorization.

An FDA news release said the pill is authorized “for the treatment of mild-to-moderate coronavirus disease (COVID-19) in adults with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options authorized by the FDA are not accessible or clinically appropriate.”

Molnupiravir was narrowly recommended by the FDA’s advisers in a 13-10 vote at the end of November after data showed it cut the risk of hospitalization or death by 30% among high-risk adults. This was lower than an earlier analysis suggesting that number could be about 50%.

Dr. Eliav Barr, senior vice president of global medical affairs at Merck, told CNN this month that he was optimistic this treatment would work against the Omicron variant.

“The Omicron variant is primarily different from the other types of Covid at the spike protein. Our drug works in completely different part of the virus. So we’re very optimistic that the drug will continue to be effective against Omicron, and we’re studying that right now.”

Pfizer pill: On Wednesday, the FDA authorized Pfizer’s antiviral pill, Paxlovid, to treat Covid-19, the first antiviral Covid-19 pill authorized in the US for ill people to take at home, before they get sick enough to be hospitalized. High-risk individuals age 12 and older who weigh at least 88 pounds and have a positive SARS-CoV-2 test are eligible for this treatment and will need to have it prescribed by a doctor.

The pill “should be initiated as soon as possible after diagnosis of Covid-19 and within five days of symptom onset,” according to an FDA statement.

Read more about the treatments:

Read original article here

Novavax’s Covid Vaccine Is Authorized in Europe

The European Commission on Monday authorized a Covid-19 vaccine made by Novavax, making it the fifth vaccine available in the 27 nations of the European Union.

“At a time where the Omicron variant is rapidly spreading, and where we need to step up vaccination and the administration of boosters, I am particularly pleased with today’s authorization of the Novavax vaccine,” Ursula von der Leyen, president of the European Commission, said in a statement.

But it’s not yet clear how well the vaccine, known as Nuvaxovid, will work against the contagious new Omicron variant. And there may not be much demand for the new vaccine in Europe, which is already flush with vaccines from Pfizer-BioNTech and other sources.

Novavax, based in Maryland, last year won $1.7 billion in support from the United States government to develop a vaccine made of proteins from the coronavirus. Despite the lavish support, Novavax lagged behind the vaccine developers Pfizer-BioNTech and Moderna, and struggled with its clinical trials and manufacturing.

Eventually, however, Novavax demonstrated that its vaccine could offer strong protection. In a final report published last week in The New England Journal of Medicine, company researchers found that Nuvaxovid was 90 percent effective against symptomatic infection and 100 percent effective against moderate to severe disease.

Protein-based vaccines have been used for decades and generally have a strong track record of safety and mild side effects. Nuvaxovid’s side effects are usually mild or moderate and clear up within a couple days.

Novavax teamed up with the Serum Institute of India as a manufacturing partner, and in recent weeks the new vaccine had a string of regulatory successes. Indonesia and the Philippines authorized the vaccine last month.

The World Health Organization last week granted Nuvaxovid an emergency-use listing, a seal of approval that accelerates the adoption of vaccines in countries that cannot conduct large-scale reviews of their own.

Already, Novavax has lined up a number of purchase orders. The company also plans to supply 1.1 billion doses to Covax, a consortium that seeks to distribute vaccines to countries around the world. In a Nov. 4 earnings call, Novavax officials said that they anticipated producing over two billion doses in 2022.

In August, the European Commission agreed to purchase up to 200 million doses of the vaccine. The commission authorized Nuvaxovid after a recommendation issued on Monday by the European Medicines Agency.

In a statement, Novavax said that it expected initial doses to arrive in Europe in January.

But Europe has been using other vaccines for nearly a year, and the European Commission has locked up an abundant supply, with an agreement for up to 2.4 billion doses from Pfizer-BioNTech alone.

On Monday, Pfizer-BioNTech announced that an agreement was reached with the European Commission to purchase over 200 million doses in 2022. Those would be in addition to the 450 million doses already set to be delivered in 2022.

Novavax is introducing its vaccine at a moment when the pandemic is undergoing a global shift. The Omicron variant, which can evade some of the immunity provided by existing vaccines, is rapidly rising to dominance in much of Europe and elsewhere.

The company is investigating how well Omicron can evade antibodies produced by two doses of Nuvaxovid but has yet to release results of the experiment.

In a small clinical trial in South Africa, Novavax found that another variant, called Beta, drastically reduced the efficacy of the vaccine to less than 50 percent. That efficacy may have been unusually low because some of the volunteers in the study had H.I.V. and thus had weakened immune systems. Novavax estimated that the efficacy of the vaccine against Beta was 60 percent in people without H.I.V.

In studies of other vaccines, researchers have found that Omicron is consistently better at evading vaccines than Beta. That raises the possibility that Nuvaxovid will prove even less effective at preventing Omicron infections than those caused by Beta.

“We can’t speculate on Omicron until we see the data,” said Alison Chartan, a spokeswoman for Novavax.

Nuvaxovid may be more useful as a source of booster shots. This month, British researchers reported that when people switched from other vaccines to Nuvaxovid for their boosters, the vaccine could raise antibody levels against the coronavirus. If the levels are high enough, they may provide strong protection against Omicron.

This month, Novavax announced it was developing an Omicron-specific version of its vaccine and said it would test the new vaccine in the next few weeks. Novavax has said that it expects to submit an application to the Food and Drug Administration in the United States by the end of December.

Read original article here

One year after FDA authorized Pfizer’s COVID vaccine, cases are on the rise

Saturday marks one year since the Food and Drug Administration authorized Pfizer’s COVID-19 vaccine — the first of three COVID-19 vaccines now in use in the United States.  

During that time, more than 480 million shots have been administered, and just over 60% of eligible Americans are fully vaccinated. But even with those protections, case numbers have gone up 22% in the past two weeks. 

Confirmed COVID cases showed up this week at an average rate of 120,000 per day, according to the U.S. Centers for Disease Control and Prevention. Ninety-nine percent of those new cases are from Delta variant, not Omicron.

The hope is that current vaccines will also be effective in beating back the Omicron variant.   

But government officials are still preparing for the worst. 

In New York, Governor Kathy Hochul issued a statewide indoor mask mandate on Friday. Anyone entering a New York business that does not have a vaccination policy is required to wear a mask.  

Hochul said now is the time to take action to stop the spread of the Omicron COVID variant. 

“We’re entering a time of uncertainty and we could either plateau here or our cases could escalate beyond control,” said Hochul. 

More Omicron variant cases surfaced this week, with at least 75 known cases in 25 states. The CDC analyzed 43 of those cases and found nearly 80% of the people afflicted are fully vaccinated. 

Additionally, CDC Director Dr. Rochelle Walensky said there was a pattern in the cases studied. 

“Over half were between the ages of 18 and 39 and about one-third reported international travel before they were diagnosed,” she said.  

 Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases and chief medical advisor to the president, continues to urge people to get vaccinated and get booster shots to protect against the virus. 

New cases increased some 37% since last week — pushing case numbers up in 44 states. 

Case numbers continue to compromise health care delivery in some places, according to St. Joseph County deputy health officer Dr. Mark Fox.  

“Not just the ability to treat COVID patients, but the ability to treat everything else,” he said. “There are surgeries being delayed for cancer, for a heart valve, for everything you can think of, and a number of patients who are boarding in the emergency room waiting for beds, so the system is really stressed right now,” said Fox.  

A survey of 250 hospitals from across the country shows that unvaccinated COVID patients are eight times more likely to require hospitalization than vaccinated people. 

Read original article here

New Ethiopia sanctions authorized by Biden executive order amid reports of atrocities

The administration did not immediately impose sanctions under the new order, but “is prepared to take aggressive action” unless the parties — including the Ethiopian government, the Eritrean government, the Tigray People’s Liberation Front, and the Amhara Regional Government — “take meaningful steps to enter into talks for a negotiated ceasefire and allow for unhindered humanitarian access,” a senior administration official told reporters.

This official said the administration is looking to see action within “weeks, not months.” Biden approved the executive order after the administration has “telegraphed for months that the parties need to change course,” a second senior administration official said.

“The ongoing conflict in northern Ethiopia is a tragedy causing immense human suffering and threatens the unity of the Ethiopian state,” Biden said in a statement Friday.

“The United States is determined to push for a peaceful resolution of this conflict, and we will provide full support to those leading mediation efforts,” Biden said in a statement.

He continued, “I join leaders from across Africa and around the world in urging the parties to the conflict to halt their military campaigns respect human rights, allow unhindered humanitarian access, and come to the negotiating table without preconditions. Eritrean forces must withdraw from Ethiopia.”

“A different path is possible but leaders must make the choice to pursue it,” the President said.

The executive order reflects a growing sense of urgency at the situation in Tigray, where humanitarian access to deliver critically needed food, fuel and medicine has been largely cut off and hundreds of thousands face famine.

CNN has uncovered evidence that mass detention, sexual violence, and killings that bear the hallmarks of genocide have occurred in Tigray. Those investigations have spurred Congress to ratchet up pressure on the administration to take action, according to one Senate aide, who noted that lawmakers on both sides of the aisle are pushing for the administration to not only name sanctions targets, but also make a determination on whether the atrocities that have taken place constitute genocide.

The aide told CNN the US Embassies in Ethiopia and Eritrea have identified names of some potential sanctions targets.

In the statement Friday, Biden said he is “appalled by the reports of mass murder, rape, and other sexual violence to terrorize civilian populations.”

The administration officials acknowledged that the situation in Tigray has deteriorated in recent months and voiced concern that violence could soon escalate as the rainy season comes to an end, allowing for greater movement in the region.

However, the first administration official said that the decision to sign the executive order but not immediately impose sanctions reflects the administration’s belief that “a different path is possible.”

“This is not a decision that this administration has taken lightly and our preference, quite frankly, is to not to use this tool,” they said. “We would prefer that the parties to the conflict work with the international community to advance discussions toward a negotiated ceasefire.”

“We want to see a prosperous, prosperous, peaceful, united Ethiopia, as well as the region in the Horn of Africa, but this ongoing protracted conflict is risking — puts all of that at risk,” they said.

‘No military solution’

This official added that they are “not optimistic about the situation on the ground and that’s why the President authorized this executive order in order to ramp up the pressure, but we are optimistic about the growing moves by regional leaders, by the (African Union) Envoy (Olusegun) Obasanjo to press for a mediated solution, and we hope that we can marshal support for these efforts.”

The situation is likely to be a “key discussion” at next week’s United Nations General Assembly in New York, the second official said, “because it is right now one of the largest humanitarian catastrophes in the world.”

“There’s a widespread consensus, outside of Ethiopia, at least, that there is no military solution to this conflict,” they said.

Friday’s executive order is broader in scope compared to previous sanctions announced in the region and will give the Treasury and State Departments authority and flexibility to identify individuals and entities responsible for the conflict if steps toward a ceasefire are not taken.

The first official emphasized that any sanctions will not be targeted at the people of Ethiopia, noting that the Treasury Department will issue general licenses laying out “clear exemptions for any development, humanitarian, and other assistance efforts, as well as critical commercial activity in Ethiopia and Eritrea.”

In May, Secretary of State Antony Blinken announced sweeping visa restrictions on “certain individuals responsible for, or complicit in, undermining resolution of the crisis in Tigray” and the US sanctioned the chief of staff of the Eritrean Defense Forces for his connection to “serious human rights abuse committed during the ongoing conflict in Tigray.”

The State Department has also “imposed restrictions on foreign assistance for Ethiopia and have brought our defense trade control policy in line with this action,” according to a State Department spokesperson.

“Security assistance programs have been suspended. A planned Millennium Challenge Corporation economic growth ‘threshold’ program also remains on hold at this time,” they said.

‘Deeply disturbing’

In a statement last week, State Department spokesperson Ned Price called “reports of human rights abuses and atrocities” by parties to the conflict in the Tigray region of Ethiopia “deeply disturbing,” saying that those “mounting reports of human rights abuses underscore the urgency of independent and credible international investigations.”

The statement was released following reporting from CNN that found bodies of Tigrayans, some of which bore signs of torture, washing up in a Sudanese town near the border with Ethiopia. Reuters recently reported that Tigrayan forces killed more than 100 civilians in a village in the Amhara region.

The Biden administration is also conducting “a law and fact-based review” about whether crimes which may amount to genocide have taken place in Tigray.

That review has been underway since at least late June. Acting Assistant Secretary of State Robert Godec told lawmakers at the time that “the administration is in full agreement that horrifying atrocities have been committed in Tigray and Secretary Blinken did say in earlier testimony, as you’ve said, that there were acts of ethnic cleansing.”

“We are in the process of a fact and law-based review to determine whether the terms crimes against humanity, genocide, and war crimes can and should be used,” he said. “The final decision on whether we’re going to use those terms is up to the Secretary of State.”

Read original article here

Covid-19 vaccine boosters are now authorized for some. Here’s what you need to know

The US Food and Drug Administration on Thursday authorized third doses of both the Pfizer/BioNTech or Moderna coronavirus vaccines for certain immunocompromised people: solid organ transplant recipients or “those who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise.”

But these doses will be considered part of the initial vaccination series for people who have not mounted an adequate immune response. A booster dose is something different. It helps refresh a waning immune response, or helps the body fight an evolving pathogen.

And many Americans who aren’t now eligible for an additional shot are wondering when it will be their turn.

What about boosters for everyone?

Covid-19 vaccine boosters are not currently needed for the general US population, but the administration is checking the data daily and will be ready if that changes, US Surgeon General Dr. Vivek Murthy said Thursday.

“We’re trying to understand if there’s a decrease in protection that’s manifesting as a significant increase in breakthrough infections, particularly breakthrough hospitalizations and deaths,” Murthy told CNN’s Erin Burnett.

Murthy said the administration is looking at data from pharmaceutical companies, private health care systems and other countries, including the UK, Israel and Canada.

“We look at that data very regularly, closely. When we see the threshold met, that’s when we’ll recommend boosters for additional people,” Murthy said. “That’s an if question. It’s a when question, and the data is going to drive our decision on that.”

However, the Biden administration is expected to lay out a Covid-19 vaccine booster strategy for all vaccinated Americans in September — with possible details on a phased rollout, starting with the most vulnerable.

The US can look to Covid-19 vaccination in Israel for an idea of what may need to be considered a month or so in the future, Andy Slavitt, former White House Covid-19 adviser, said Thursday. Israel has authorized Covid-19 vaccine booster doses for adults older than 50, becoming one of the first countries in the world to make such a move.

“Israel began their vaccination process a little bit ahead of us, so I think in many respects, we’ve been looking to them — and to a certain extent, the UK — for what we can expect, as well as the people who participated in the original clinical trials of the vaccines in 2020,” Slavitt told CNN’s Anderson Cooper on Thursday. “Those three things together, generally speaking, give us a sense of what to predict for the future.”

Currently three coronavirus vaccines are authorized for emergency use in the United States — the two-dose Pfizer/BioNTech vaccine for people 12 and older, the two-dose Moderna vaccine and the single-dose Johnson & Johnson vaccines for everyone 18 and older.

Some researchers and health officials suspect antibodies against coronavirus produced through the vaccines may diminish over time — possibly after a year or more — and may not protect as well against coronavirus variants that could emerge.

In July, Israel’s health ministry said in a statement that it had seen efficacy of Pfizer’s vaccine drop from more than 90% to about 64% as the B.1.617.2 or Delta variant spread.

That might mean a vaccinated person would need a booster dose of vaccine to stay protected against the original coronavirus strain and newly emerging variants — including the Delta variant — in a way similar to how a tetanus booster is recommended every 10 years or different flu vaccines are recommended each year.

In the case of Covid-19 vaccines, it remains unknown for how long immune protection lasts, but vaccine developers and health officials know it may not be forever — and that emerging variants could evade immunity.

“There is a little nuance with Covid-19 vaccines,” Dr. William Moss, professor and executive director of the International Vaccine Access Center at Johns Hopkins Bloomberg School of Public Health, told CNN in May.

While typical booster doses use the same vaccine formula someone previously received to remind the immune system about immunity to a pathogen, Moss said, any future boosters for the Covid-19 shot could use altered vaccine formulas.

For instance, the companies Pfizer and BioNTech said in a statement that while a third dose of their coronavirus vaccine “has the potential to preserve the highest levels of protective efficacy against all currently tested variants including Delta, the companies are remaining vigilant and are developing an updated version of the Pfizer-BioNTech COVID-19 vaccine that targets the full spike protein of the Delta variant.”

What happens if you skip the booster?

Whether booster coronavirus vaccine doses are modified or not, missing a booster dose — if one is recommended in the future — could leave someone less protected against Covid-19.

“A person who skipped a booster is placing themselves at higher risk of getting infected, and getting disease from the SARS-Coronavirus-2, but I would also expect that they’re going to have some partial immunity and so they may be protected against more severe disease,” Moss said in May. SARS-CoV-2 is the virus that causes Covid-19.

“They’re just at higher risk of infection and disease than someone who got the booster, but they have more immunity than someone who was never vaccinated.”

Scientists are also currently investigating whether it makes a difference if someone gets the same type of vaccine as a booster as the original dose administered.

Then there is the question of mixing and matching doses.

Researchers in the United Kingdom reported in May that people who got mixed doses of coronavirus vaccines — receiving a different vaccine type as a second dose than the first dose — appear to be more likely to experience mild side effects such as fever, chills, fatigue or headache.

But the side effects following mix-and-match vaccinations were short-lived and there were no other safety concerns, the researchers reported in the Lancet medical journal.

Who is making booster shots?

All three companies that currently have authorized coronavirus vaccines in the United States — Pfizer, Moderna and Johnson & Johnson — are investigating the potential use of boosters.

“The data that I see coming, they are supporting the notion that likely there will be a need for a booster somewhere between eight and 12 months,” Pfizer CEO Albert Bourla told Axios in May. “But that remains to be seen and I believe in one, two months we will have enough data to speak about it with much higher scientific certainty.”

The first dose of Pfizer’s coronavirus vaccine in the United States was administered on December 14, 2020.

Moderna is currently conducting booster shot trials too.

The fight against the coronavirus pandemic is expected to continue through next year due to the emergence of variants, Dr. Stephen Hoge, president of Moderna, said during an earnings call in early May.

“We think this is just the beginning,” Hoge said. “Therefore, we’re committed as a company to make as many updates to the vaccine, to add as many variants as we think are necessary, to ensure that when people receive a booster, it provides the broadest immune protection against the widest range of variants.”

Johnson & Johnson is also looking into the potential for boosters, the company told CNN in May.

Johnson & Johnson’s coronavirus vaccine, along with Pfizer’s, Moderna’s, and four others, are being tested as seasonal boosters in a study called Cov-Boost being conducted by the UK’s National Institute for Health Research and the University of Southampton.

The biotechnology company Novavax has developed a coronavirus vaccine that its chief executive officer Stanley Erck believes could be used as a booster shot for people who have already been vaccinated. The company plans to apply for emergency use authorization of its vaccine in the United States in the fourth quarter of 2021.

Who has to OK the Covid-19 booster shots?

The decision to broadly use Covid-19 boosters is expected to involve two agencies — the FDA and the CDC — and the regulatory process to get the shots into arms could vary depending on whether the booster is the same vaccine that was originally used or is a modified version.

“So, if it’s the same vaccine, my understanding is that what would have to happen is that the CDC would have to recommend an additional dose with details around when that should occur,” Moss said in May.

In other words, the FDA must give authorization for the vaccines to be used in new ways outside the existing authorization. Then, the CDC advises on whether to actually use the vaccine as authorized by the FDA.

If it’s a modified vaccine, “this is where things get interesting and I don’t think we quite know,” Moss said, but added that the regulatory process could be similar to what happens with flu vaccines each year.

“Technically, whenever a vaccine like that is modified, it’s often considered a new vaccine and has to go through the whole process again. But there is a precedent, obviously, with influenza virus vaccines, not to do that,” Moss said. “So, the influenza vaccine each year doesn’t have to go through a large Phase 3 trial.”

That’s because the vaccine technology stays the same, and the only change is the strain of flu virus that the vaccine targets.

How is it determined that someone needs a booster?

There is no definite way to know someone needs an additional dose of coronavirus vaccine — but so far, studies on booster doses have measured antibody levels.

Cancer patients who receive the Covid-19 vaccine, for example, are less likely to develop protective antibodies, according to two studies published this week in the journal JAMA Oncology. Antibodies are proteins the body makes to fight infection.

Yet the researchers noted that the test used to detect Covid-19 antibodies does not provide information about T-cell–based immunity or clinical outcomes related to potential Covid-19 infection. T-cells and B-cells are other components of the immune system with immune memory that can protect the body against infection.

In one of those studies, researchers in Israel followed up on initial findings showing anti-spike Covid-19 antibody levels were significantly lower among cancer patients 5.5 weeks after the second dose of an mRNA Covid-19 vaccine, compared to non-cancer patients.

The team looked at 95 cancer patients and 66 control patients from their initial analysis about four months after their second vaccine dose. About 87% of cancer patients and 100% of patients in the control group showed anti-spike antibodies, and antibody levels were still significantly lower in the cancer patients. The researchers noted that the median antibody level for both groups decreased over time.

Separately, among organ transplant recipient patients in a Johns Hopkins University study who had no measurable antibodies after receiving two doses of vaccine, one-third of them saw a rise in antibodies after a third dose — and among those with low antibody levels after two doses, all of them saw an increase after a third dose.
Dr. Dorry Segev, an author of the study and founder of the Epidemiology Research Group in Organ Transplantation at Johns Hopkins University, told CNN in June that it’s unclear what antibody level provides protective immunity. “We don’t know if you need the same off-the-charts level of antibodies that people with normal immune systems have,” he said.

How often will you need a Covid-19 booster?

Some experts predict that a coronavirus vaccine booster dose might be needed annually — but despite such predictions, Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, has said that the bottom line is no one knows yet.

Still, the US is prepared for the possibility, Fauci said during a White House Covid-19 Response Team briefing in August.

Fauci said he believes eventually everyone will need a booster to maintain full protection from the vaccine.

“We are evaluating this on a day by day, week by week, month by month basis, looking at any of a number of studies, both international and domestic.” he said.

He added that if it looks like immunity is waning, or a variant is evading the protection offered by current vaccines, then health officials will be ready to recommend boosters.

Eventually, it’s possible that a booster dose of Covid-19 vaccine might just be part of the completion of immunization, not an annual requirement to revaccinate, Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, said last week.

“I don’t think that we want to think that these vaccines have somehow failed us,” Marks said at a discussion hosted by the Covid-19 Vaccine Education and Equity Project.

“It may simply be that to get the kind of really good immunity against Covid-19 that we get with some other vaccines, it may take a series of three vaccinations, much the same way that hepatitis B for adults and multiple childhood vaccination primary series, you need to get a vaccination, you know, 0, 1; or 0, 2 and 4; or 0, 2 and 6 months.”

CNN’s Virginia Langmaid, Lauren Mascarenhas, Michael Nedelman and Jen Christensen contributed to this report.

Read original article here

IRS authorized to access information on Circle’s crypto traders to nab tax cheats

A U.S. federal court has granted authorization to the Internal Revenue Service, or IRS, to serve a John Doe summons to fintech firm Circle seeking all information on U.S. taxpayers who traded at least $20,000 worth of crypto assets on its platforms between 2016 and 2020.

The summons will apply to Circle Internet Financial Inc. including all “predecessors, subsidiaries, divisions, and affiliates, including Poloniex LLC.”

According to the Department of Justice’s announcement, Judge Richard Stearns concluded there is “reasonable basis for believing that cryptocurrency users may have failed to comply with federal tax laws.”

The document also notes the IRS “does not allege that Circle has engaged in any wrongdoing in connection with its digital currency exchange business,” adding:

“The summons seeks information related to the IRS’s ‘investigation of an ascertainable group or class of persons’ that the IRS has reasonable basis to believe ‘may have failed to comply with any provision of any internal revenue laws.’”

A Circle representative told Law360: “We’re reviewing [the summons], and of course expect to work collaboratively with the IRS in responding to the court order.”

Attorney General David Hubbert of the Department of Justice’s Tax Division said: “Those who transact with cryptocurrency must meet their tax obligations like any other taxpayer. The Department of Justice will continue to work with the IRS to ensure that cryptocurrency owners are paying their fair share of taxes.”

Circle was founded in October 2013 by Jeremy Allaire and Sean Neville, with the company launching a Bitcoin wallet the following year that later became its crypto payments application, Circle Pay. In 2018, Circle launched USD Coin in partnership with Coinbase, which is now the second-largest stablecoin by market cap.

Circle purchased the popular digital asset exchange Poloniex in 2018, but announced Poloniex would “spin out” into a new company backed by an investment group with ties to Tron’s Justin Sun the following year.

Read original article here